Hospira beats by $0.05, reports revs in-line
Reports Q2 (Jun) earnings of $0.85 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $0.80; revenues rose 4.2% year/year to $1.18 bln vs the $1.18 bln consensus.
- Given the announcement early in Q1 that Hospira and Pfizer (PFE) had entered into a merger agreement, the company is not providing annual projections for 2015.
- "Hospira continues to see good momentum across our product lines, resulting in strong sales and profitability in the first half of the year...Complementing our strong financial performance is our continued progress on many fronts, including new generic injectable product launches, advancements in our on-market biosimilars and related pipeline, and execution of our Device Strategy."